Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression

NCT04180371 is registered in ClinicalTrials.gov with BicycleTx Limited as lead sponsor.

NCT NCT04180371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04180371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Lead sponsor
BicycleTx Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 7, 2019
Completion date
July 31, 2027
Enrollment
288 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor historically known for high epha2 expression, gastric/upper gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, ovarian cancer, triple negative breast cancer, urothelial cancer